Early test of 3-Month schizophrenia shot begins

NCT ID NCT06674694

Summary

This is an early safety study for a new long-acting injection of the medication brexpiprazole, intended for schizophrenia. It will test single doses in 56 healthy volunteers and people with stable schizophrenia to check for side effects and see how the drug moves through the body over 90 days. The main goal is to see if the injection is safe and well-tolerated at different dose levels.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Anding Hospital Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 100000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.